Management of cardiovascular disease in patients with psoriasis

References

• Parisi R, Symmons DPM, Griffiths CEM, et al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377–385.
   PubMed Web of Science ®Google Scholar
• McDonald CJ, Calabresi P. Occlusive vascular disease in psoriatic patients. N Engl J Med. 1973;288(17):912.
   PubMed Web of Science ®Google Scholar
• McDonald CJ, Calabresi P. Thromboembolic disorders associated with psoriasis. Arch Dermatol. 1973;107(6):918.
   PubMedGoogle Scholar
• Mallbris L, Akre O, Granath F, et al. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19(3):225–230.
   PubMed Web of Science ®Google Scholar
• Mallbris L, Granath F, Hamsten A, et al. Psoriasis is associated with lipid abnormalities at the onset of skin disease. J Am Acad Dermatol. 2006;54(4):614–621.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Neimann AL, Shin DB, et al. Risk of myocardial infarction in patients with psoriasis. Jama. 2006;296(14):1735–1741.
   PubMed Web of Science ®Google Scholar
• Gelfand JM, Troxel AB, Lewis JD, et al. The risk of mortality in patients with psoriasis: results from a population-based study. Arch Dermatol. 2007;143(12):1493–1499.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Troxel AB, Mehta NN, et al. Psoriasis and cardiovascular risk: strength in numbers part 3. J Invest Dermatol. 2015;135(9):2148–2150.
   PubMed Web of Science ®Google Scholar
• Alexandroff AB, Pauriah M, Camp RD, et al. More than skin deep: atherosclerosis as a systemic manifestation of psoriasis. Br J Dermatol. 2009;161(1):1–7.
   PubMed Web of Science ®Google Scholar
• Libby P, Ridker PM, Hansson GK, et al. Inflammation in atherosclerosis: from pathophysiology to practice. J Am Coll Cardiol. 2009;54(23):2129–2138.
   PubMed Web of Science ®Google Scholar
• Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352(16):1685–1695.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Skov L, Gislason G, et al. Cardiovascular outcomes and systemic anti-inflammatory drugs in patients with severe psoriasis: 5-year follow-up of a Danish nationwide cohort. J Eur Acad Dermatol Venereol. 2015;29(6):1128–1134.
   PubMed Web of Science ®Google Scholar
• Abuabara K, Lee H, Kimball AB. The effect of systemic psoriasis therapies on the incidence of myocardial infarction: a cohort study. Br J Dermatol. 2011;165(5):1066–1073.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Brezinski EA, Follansbee MR, et al. Effects of biologic agents and other disease-modifying antirheumatic drugs on cardiovascular outcomes in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des. 2014;20(4):500–512.
   PubMed Web of Science ®Google Scholar
• Chen YJ, Chang YT, Shen JL, et al. Association between systemic antipsoriatic drugs and cardiovascular risk in patients with psoriasis with or without psoriatic arthritis: a nationwide cohort study. Arthritis Rheum. 2012;64(6):1879–1887.
   PubMed Web of Science ®Google Scholar
• Mehta NN, Yu Y, Pinnelas R, et al. Attributable risk estimate of severe psoriasis on major cardiovascular events. Am J Med. 2011;124(8):775e1–775e6.
   Web of Science ®Google Scholar
• Mehta NN, Krishnamoorthy P, Yu Y, et al. The impact of psoriasis on 10-year Framingham risk. J Am Acad Dermatol. 2012;67(4):796–798.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Farina S, Giordano MV, et al. Usefulness of the Framingham risk score in patients with chronic psoriasis. Am J Cardiol. 2010;106(12):1754–1757.
   PubMed Web of Science ®Google Scholar
• Gyldenlove M, Jensen P, Linneberg A, et al. Psoriasis and the Framingham risk score in a Danish hospital cohort. Int J Dermatol. 2014;53(9):1086–1090.
   PubMed Web of Science ®Google Scholar
• Task Force for the management of dyslipidaemias of the European Society of Cardiology, the European Atherosclerosis Society, Catapano AL, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(Suppl 1):S1–S44.
   PubMed Web of Science ®Google Scholar
• Peters MJ, Symmons DP, McCarey D, et al. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis. 2010;69(2):325–331.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Boehncke S. Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives. Curr Rheumatol Rep. 2012;14(4):343–348.
   PubMed Web of Science ®Google Scholar
• Samarasekera EJ, Neilson JM, Warren RB, et al. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133(10):2340–2346.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Gislason GH, Charlot M, et al. Psoriasis is associated with clinically significant cardiovascular risk: a Danish nationwide cohort study. J Intern Med. 2011;270(2):147–157.
   PubMed Web of Science ®Google Scholar
• Ogdie A, Yu Y, Haynes K, et al. Risk of major cardiovascular events in patients with psoriatic arthritis, psoriasis and rheumatoid arthritis: a population-based cohort study. Ann Rheum Dis. 2015;74(2):326–332.
   PubMed Web of Science ®Google Scholar
• Salahadeen E, Torp-Pedersen C, Gislason G, et al. Nationwide population-based study of cause-specific death rates in patients with psoriasis. J Eur Acad Dermatol Venereol. 2015;29(5):1002–1005.
   PubMed Web of Science ®Google Scholar
• Gulliver WP, Macdonald D, Gladney N, et al. Long-term prognosis and comorbidities associated with psoriasis in the Newfoundland and Labrador founder population. J Cutan Med Surg. 2011;15(1):37–47.
   PubMed Web of Science ®Google Scholar
• Gaeta M, Castelvecchio S, Ricci C, et al. Role of psoriasis as independent predictor of cardiovascular disease: a meta-regression analysis. Int J Cardiol. 2013;168(3):2282–2288.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Gislason GH, Jorgensen CH, et al. Psoriasis and risk of atrial fibrillation and ischaemic stroke: a Danish nationwide cohort study. Eur Heart J. 2012;33(16):2054–2064.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Gislason GH, Lindhardsen J, et al. Prognosis following first-time myocardial infarction in patients with psoriasis: a Danish nationwide cohort study. J Intern Med. 2011;270(3):237–244.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Gislason GH, Lindhardsen J, et al. Psoriasis carries an increased risk of venous thromboembolism: a Danish nationwide cohort study. PLoS One. 2011;6(3):e18125.
   PubMed Web of Science ®Google Scholar
• Khalid U, Ahlehoff O, Gislason GH, et al. Psoriasis and risk of heart failure: a nationwide cohort study. Eur J Heart Fail. 2014;16(7):743–748.
   PubMed Web of Science ®Google Scholar
• Parisi R, Rutter MK, Lunt M, et al. Psoriasis and the risk of major cardiovascular events: cohort study using the clinical practice research datalink. J Invest Dermatol. 2015;135(9):2189–2197.
   PubMed Web of Science ®Google Scholar
• Dowlatshahi EA, van der Voort EA, Arends LR, et al. Markers of systemic inflammation in psoriasis: a systematic review and meta-analysis. Br J Dermatol. 2013;169(2):266–282.
   PubMed Web of Science ®Google Scholar
• Mason JC, Libby P. Cardiovascular disease in patients with chronic inflammation: mechanisms underlying premature cardiovascular events in rheumatologic conditions. Eur Heart J. 2015;36(8):482–489c.
   PubMed Web of Science ®Google Scholar
• Wang Y, Gao H, Loyd CM, et al. Chronic skin-specific inflammation promotes vascular inflammation and thrombosis. J Invest Dermatol. 2012;132(8):2067–2075.
   PubMed Web of Science ®Google Scholar
• Boehncke WH, Boehncke S, Tobin AM, et al. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol. 2011;20(4):303–307.
   PubMed Web of Science ®Google Scholar
• Balci DD, Balci A, Karazincir S, et al. Increased carotid artery intima-media thickness and impaired endothelial function in psoriasis. J Eur Acad Dermatol Venereol. 2009;23(1):1–6.
   PubMed Web of Science ®Google Scholar
• Gyldenlove M, Storgaard H, Holst JJ, et al. Patients with psoriasis are insulin resistant. J Am Acad Dermatol. 2015;72(4):599–605.
   PubMed Web of Science ®Google Scholar
• Dave J, Ahlman MA, Lockshin BN, et al. Vascular inflammation in psoriasis localizes to the arterial wall using a novel imaging technique. J Am Acad Dermatol. 2014;70(6):1137–1138.
   PubMed Web of Science ®Google Scholar
• Mehta NN, Yu Y, Saboury B, et al. Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol. 2011;147(9):1031–1039.
   PubMedGoogle Scholar
• Mehta NN, Torigian DA, Gelfand JM, et al. Quantification of atherosclerotic plaque activity and vascular inflammation using [18-F] fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT). J Vis Exp. 2012;63:e3777.
   PubMed Web of Science ®Google Scholar
• Hjuler KF, Bottcher M, Vestergaard C, et al. Increased prevalence of coronary artery disease in severe psoriasis and severe atopic dermatitis. Am J Med. 2015;128(12):1325–34e2.
   PubMed Web of Science ®Google Scholar
• Mehta NN, Li R, Krishnamoorthy P, et al. Abnormal lipoprotein particles and cholesterol efflux capacity in patients with psoriasis. Atherosclerosis. 2012;224(1):218–221.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the Cardiovascular Inflammation Reduction Trial (CIRT). J Thromb Haemost. 2009;7(Suppl 1):332–339.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes. 2012;2:e54.
   PubMed Web of Science ®Google Scholar
• Al-Mutairi N, Nour T. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial. Expert Opin Biol Ther. 2014;14(6):749–756.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. Psoriasis and the risk of diabetes mellitus: a systematic review and meta-analysis. JAMA Dermatology. 2013;149(1):84–91.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Armstrong EJ. The association between psoriasis and hypertension: a systematic review and meta-analysis of observational studies. J Hypertens. 2013;31(3):433–442; discussion 42-3.
   PubMed Web of Science ®Google Scholar
• Khalid U, Hansen PR, Gislason GH, et al. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care. 2013;36(8):2402–2407.
   PubMed Web of Science ®Google Scholar
• Torres T, Bettencourt N, Mendonca D, et al. Epicardial adipose tissue and coronary artery calcification in psoriasis patients. J Eur Acad Dermatol Venereol. 2015;29(2):270–277.
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Harskamp CT, Dhillon JS, et al. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014;170(2):304–314.
   PubMed Web of Science ®Google Scholar
• Egeberg A, Bruun LE, Mallbris L, et al. Family history predicts major adverse cardiovascular events in young adults with psoriasis. J Am Acad Dermatol. 2016. [In press]
   PubMed Web of Science ®Google Scholar
• Choy E, Sattar N. Interpreting lipid levels in the context of high-grade inflammatory states with a focus on rheumatoid arthritis: a challenge to conventional cardiovascular risk actions. Ann Rheum Dis. 2009;68(4):460–469.
   PubMed Web of Science ®Google Scholar
• Holzer M, Wolf P, Inzinger M, et al. Anti-psoriatic therapy recovers high-density lipoprotein composition and function. J Invest Dermatol. 2014;134(3):635–642.
   PubMed Web of Science ®Google Scholar
• Roubille C, Richer V, Starnino T, et al. The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2015;74(3):480–489.
   PubMed Web of Science ®Google Scholar
• Prodanovich S, Ma F, Taylor JR, et al. Methotrexate reduces incidence of vascular diseases in veterans with psoriasis or rheumatoid arthritis. J Am Acad Dermatol. 2005;52(2):262–267.
   PubMed Web of Science ®Google Scholar
• Ryan C, Leonardi CL, Krueger JG, et al. Association between biologic therapies for chronic plaque psoriasis and cardiovascular events: a meta-analysis of randomized controlled trials. Jama. 2011;306(8):864–871.
   PubMed Web of Science ®Google Scholar
• Martin JA, Laube S, Edwards C, et al. Rate of acute adverse events for narrow-band UVB and Psoralen-UVA phototherapy. Photodermatol Photoimmunol Photomed. 2007;23(2–3):68–72.
   PubMed Web of Science ®Google Scholar
• Robert N, Wong GW, Wright JM. Effect of cyclosporine on blood pressure. Cochrane Database Syst Rev. 2010;1:CD007893.
   PubMed Web of Science ®Google Scholar
• Stiller MJ, Pak GH, Kenny C, et al. Elevation of fasting serum lipids in patients treated with low-dose cyclosporine for severe plaque-type psoriasis. An assessment of clinical significance when viewed as a risk factor for cardiovascular disease. J Am Acad Dermatol. 1992;27(3):434–438.
   PubMed Web of Science ®Google Scholar
• Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29(12):2728–2729.
   PubMed Web of Science ®Google Scholar
• van der Linden MW, Penning-van Beest FJ, Nijsten T, et al. Topical corticosteroids and the risk of diabetes mellitus: a nested case-control study in the Netherlands. Drug Saf. 2009;32(6):527–537.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zhao P, Li A, et al. Effects of methotrexate on plasma cytokines and cardiac remodeling and function in postmyocarditis rats. Mediators Inflamm. 2009;2009:389720.
   PubMed Web of Science ®Google Scholar
• Everett BM, Pradhan AD, Solomon DH, et al. Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis. Am Heart J. 2013;166(2):199–207e15.
   PubMed Web of Science ®Google Scholar
• Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. Jama. 2011;305(24):2525–2531.
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Follansbee MR, Armstrong EJ, et al. Endothelial dysfunction and the effects of TNF inhibitors on the endothelium in psoriasis and psoriatic arthritis: a systematic review. Curr Pharm Des. 2014;20(4):513–528.
   PubMed Web of Science ®Google Scholar
• Pina T, Corrales A, Lopez-Mejias R, et al. Anti-tumor necrosis factor-alpha therapy improves endothelial function and arterial stiffness in patients with moderate to severe psoriasis: A 6-month prospective study. J Dermatol. 2016 [Epub ahead of print].
   Web of Science ®Google Scholar
• Wu JJ, Poon KY, Channual JC, et al. Association between tumor necrosis factor inhibitor therapy and myocardial infarction risk in patients with psoriasis. Arch Dermatol. 2012;148(11):1244–1250.
   PubMed Web of Science ®Google Scholar
• Singh JA, Wells GA, Christensen R, et al. Adverse effects of biologics: a network meta-analysis and cochrane overview. Cochrane Database Syst Rev. 2011;2:CD008794.
   PubMed Web of Science ®Google Scholar
• Hauer AD, Uyttenhove C, De Vos P, et al. Blockade of interleukin-12 function by protein vaccination attenuates atherosclerosis. Circulation. 2005;112(7):1054–1062.
   PubMed Web of Science ®Google Scholar
• Rios-Navarro C, de Pablo C, Collado-Diaz V, et al. Differential effects of anti-TNF-alpha and anti-IL-12/23 agents on human leukocyte-endothelial cell interactions. Eur J Pharmacol. 2015;765:355–365.
   PubMed Web of Science ®Google Scholar
• Paul C, Cather J, Gooderham M, et al. Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2). Br J Dermatol. 2015;173(6):1387–1399.
   PubMed Web of Science ®Google Scholar
• Papp KA, Menter MA, Abe M, et al. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015;173(4):949–961.
   PubMed Web of Science ®Google Scholar
• Torres T, Raposo I, Selores M. IL-17 blockade in psoriasis: friend or foe in cardiovascular risk? Am J Clin Dermatol. 2016;17(2):107–112.
   PubMed Web of Science ®Google Scholar
• de Boer OJ, van der Meer JJ, Teeling P, et al. Differential expression of interleukin-17 family cytokines in intact and complicated human atherosclerotic plaques. J Pathol. 2010;220(4):499–508.
   PubMed Web of Science ®Google Scholar
• Erbel C, Akhavanpoor M, Okuyucu D, et al. IL-17A influences essential functions of the monocyte/macrophage lineage and is involved in advanced murine and human atherosclerosis. J Immunol. 2014;193(9):4344–4355.
   PubMed Web of Science ®Google Scholar
• Gistera A, Robertson AK, Andersson J, et al. Transforming growth factor-beta signaling in T cells promotes stabilization of atherosclerotic plaques through an interleukin-17-dependent pathway. Sci Transl Med. 2013;5(196):196ra00.
   Web of Science ®Google Scholar
• Taleb S, Romain M, Ramkhelawon B, et al. Loss of SOCS3 expression in T cells reveals a regulatory role for interleukin-17 in atherosclerosis. J Exp Med. 2009;206(10):2067–2077.
   PubMed Web of Science ®Google Scholar
• Simon T, Taleb S, Danchin N, et al. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. Eur Heart J. 2013;34(8):570–577.
   PubMed Web of Science ®Google Scholar
• Ryoo JY, Yang HJ, Ji E, et al. Meta-analysis of the efficacy and safety of secukinumab for the treatment of plaque psoriasis. Ann Pharmacother. 2016;50(5):341–351.
   PubMed Web of Science ®Google Scholar
• Gordon KB, Leonardi CL, Lebwohl M, et al. A 52-week, open-label study of the efficacy and safety of ixekizumab, an anti-interleukin-17A monoclonal antibody, in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;71(6):1176–1182.
   PubMed Web of Science ®Google Scholar
• Brauchli YB, Jick SS, Meier CR. Statin use and risk of first-time psoriasis diagnosis. J Am Acad Dermatol. 2011;65(1):77–83.
   PubMed Web of Science ®Google Scholar
• Wolkenstein P, Revuz J, Roujeau JC, et al. Psoriasis in France and associated risk factors: results of a case-control study based on a large community survey. Dermatology. 2009;218(2):103–109.
   PubMed Web of Science ®Google Scholar
• Chodick G, Weitzman D, Shalev V, et al. Adherence with statins and the risk of psoriasis: a population-based cohort study. Br J Dermatol. 2015;173(2):480–487.
   PubMed Web of Science ®Google Scholar
• Naseri M, Hadipour A, Sepaskhah M, et al. The remarkable beneficial effect of adding oral simvastatin to topical betamethasone for treatment of psoriasis: a double-blind, randomized, placebo-controlled study. Niger Med J Nat Assoc Res Doctors Niger. 2010;19(1):58–61.
   PubMedGoogle Scholar
• Hilgendorff A, Muth H, Parviz B, et al. Statins differ in their ability to block NF-kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther. 2003;41(9):397–401.
   PubMed Web of Science ®Google Scholar
• Ivanov II, McKenzie BS, Zhou L, et al. The orphan nuclear receptor RORgamma T directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell. 2006;126(6):1121–1133.
   PubMed Web of Science ®Google Scholar
• Fujita-Sato S, Ito S, Isobe T, et al. Structural basis of digoxin that antagonizes RORgamma T receptor activity and suppresses Th17 cell differentiation and interleukin (IL)-17 production. J Biol Chem. 2011;286(36):31409–31417.
   PubMed Web of Science ®Google Scholar
• Lee J, Baek S, Lee J, et al. Digoxin ameliorates autoimmune arthritis via suppression of Th17 differentiation. Int Immunopharmacol. 2015;26(1):103–111.
   PubMed Web of Science ®Google Scholar
• Ahlehoff O, Skov L, Gislason G, et al. Pharmacological undertreatment of coronary risk factors in patients with psoriasis: observational study of the Danish nationwide registries. PLoS One. 2012;7(4):e36342.
   PubMed Web of Science ®Google Scholar
• Kimball AB, Szapary P, Mrowietz U, et al. Underdiagnosis and undertreatment of cardiovascular risk factors in patients with moderate to severe psoriasis. J Am Acad Dermatol. 2012;67(1):76–85.
   PubMed Web of Science ®Google Scholar
• Gisondi P, Del Giglio M, Di Francesco V, et al. Weight loss improves the response of obese patients with moderate-to-severe chronic plaque psoriasis to low-dose cyclosporine therapy: a randomized, controlled, investigator-blinded clinical trial. Am J Clin Nutr. 2008;88(5):1242–1247.
   PubMed Web of Science ®Google Scholar
• Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the severity of psoriasis: a randomized clinical study. JAMA Dermatology. 2013;149(7):795–801.
   PubMed Web of Science ®Google Scholar
• Jensen P, Zachariae C, Christensen R, et al. Effect of weight loss on the cardiovascular risk profile of obese patients with psoriasis. Acta Derm Venereol. 2014;94(6):691–694.
   PubMed Web of Science ®Google Scholar
• Do YK, Lakhani N, Malhotra R, et al. Association between psoriasis and leisure-time physical activity: findings from the national health and nutrition examination survey. J Dermatol. 2015;42(2):148–153.
   PubMed Web of Science ®Google Scholar
• Li W, Han J, Choi HK, et al. Smoking and risk of incident psoriasis among women and men in the United States: a combined analysis. Am J Epidemiol. 2012;175(5):402–413.
   PubMed Web of Science ®Google Scholar
• Zou L, Lonne-Rahm SB, Helander A, et al. Alcohol intake measured by phosphatidylethanol in blood and the lifetime drinking history interview are correlated with the extent of psoriasis. Dermatology. 2015;230(4):375–380.
   PubMed Web of Science ®Google Scholar
• Gerdes S, Dethlefs B, Personke Y, et al. Online weight-loss coaching for patients with psoriasis: results of a pilot study. Br J Dermatol. 2016;174(3):674–676.
   PubMed Web of Science ®Google Scholar
• WHO. Global Report on Psoriasis. 2016 [cited 2016 Mar 29]. Available from: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf
   Google Scholar
• Sundhedsstyrelsen. National Klinisk Retningslinje for Psoriasis. 2016 [cited 2016 Mar 29]. Available from: https://sundhedsstyrelsen.dk/da/udgivelser/2016/~/media/8A7C8C59AD5249C2B433530466C1EDB6.ashx
   Google Scholar
• Kimball AB, Gladman D, Gelfand JM, et al. National psoriasis foundation clinical consensus on psoriasis comorbidities and recommendations for screening. J Am Acad Dermatol. 2008;58(6):1031–1042.
   PubMed Web of Science ®Google Scholar
• Tablazon IL, Al-Dabagh A, Davis SA, et al. Risk of cardiovascular disorders in psoriasis patients: current and future. Am J Clin Dermatol. 2013;14(1):1–7.
   PubMed Web of Science ®Google Scholar
• DDS. Anbefalinger for vurdering af risiko for kardiovaskulær sygdom hos patienter med psoriasis og psoriasis artrit. 2016 [cited 2016 Mar 16]. Available from: http://www.dds.nu/wp-content/uploads/2012/08/Anbefalinger-for-vurdering-af-risikoen-for-kardiovaskulær-sygdom.pdf
   Google Scholar
• Banerjee C, Moon YP, Paik MC, et al. Duration of diabetes and risk of ischemic stroke: the Northern Manhattan study. Stroke. 2012;43(5):1212–1217.
   PubMed Web of Science ®Google Scholar
• Masuda H, Miyazaki T, Shimada K, et al. Disease duration and severity impacts on long-term cardiovascular events in Japanese patients with rheumatoid arthritis. J Cardiol. 2014;64(5):366–370.
   PubMed Web of Science ®Google Scholar
• Fenerty SD, West C, Davis SA, et al. The effect of reminder systems on patients’ adherence to treatment. Patient Prefer Adherence. 2012;6:127–135.
   PubMed Web of Science ®Google Scholar
• Ridker PM. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? Trans Am Clin Climatol Assoc. 2013;124:174–190.
   PubMedGoogle Scholar